Search results
Showing 1 to 15 of 1001 results for public health medicine & health
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]
In development Reference number: GID-TA11572 Expected publication date: 21 May 2026
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
In development Reference number: GID-TA11373 Expected publication date: 28 May 2026
In development Reference number: GID-TA10726 Expected publication date: 13 May 2026
In development Reference number: GID-TA11023 Expected publication date: 28 May 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development Reference number: GID-TA11091 Expected publication date: 04 June 2026
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]
In development Reference number: GID-TA11386 Expected publication date: 04 June 2026
In development Reference number: GID-TA11440 Expected publication date: 03 June 2026
In development Reference number: GID-TA11823 Expected publication date: 03 June 2026
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
In development Reference number: GID-TA11414 Expected publication date: 10 June 2026
Hepatitis B and C testing: people at risk of infection (PH43)
This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
View recommendations for MPG2Show all sections
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
In development Reference number: GID-TA10620 Expected publication date: 12 June 2026
Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.
Community pharmacies: promoting health and wellbeing (NG102)
This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.